Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | PREP | P48147 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13445 | 1.00 | HPGD (0.71) | HPGDSMN1; SMN2USP2EPHX1MEN1 | |
| SCHEMBL3830876 | 1.00 | HPGD (0.71) | HPGDSMN1; SMN2USP2EPHX1MEN1 | |
| SCHEMBL19864905 | 1.00 | HPGD (0.71) | HPGDSMN1; SMN2USP2EPHX1MEN1 | |
| SCHEMBL2077166 | 1.00 | HPGD (0.71) | HPGDSMN1; SMN2USP2EPHX1MEN1 | |
| SCHEMBL18432213 | 1.00 | HPGD (0.71) | HPGDSMN1; SMN2USP2EPHX1MEN1 | |
| SCHEMBL19864899 | 1.00 | HPGD (0.71) | HPGDSMN1; SMN2USP2EPHX1MEN1 | |
| SCHEMBL19852529 | 1.00 | HPGD (0.71) | HPGDSMN1; SMN2USP2EPHX1MEN1 | |
| SCHEMBL18097955 | 1.00 | HPGD (0.71) | HPGDSMN1; SMN2USP2EPHX1MEN1 | |
| SCHEMBL21707988 | 1.00 | HPGD (0.71) | HPGDSMN1; SMN2USP2EPHX1MEN1 | |
| Ammonia Solution, Strong SCHEMBL20236062 | 0.98 | HPGD (0.69) | HPGDSMN1; SMN2USP2EPHX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114245753-A | Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy | 江苏康宁杰瑞生物制药有限公司 | 2022-03-25 | — | — | CN | claimed |
| EP-1794129-B1 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-30 | — | — | EP | claimed |
| US-7402670-B2 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | claimed |
| US-20060069250-A1 | Synthesis by chiral diamine-mediated asymmetric alkylation | DENG XIAOHU | 2006-03-30 | — | — | US | claimed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| CN-119894896-A | Inhibitors of green peroxidase | 阿斯利康(瑞典)有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025077770-A1 | FUSED RING COMPOUND AND USE THEREOF IN KRAS INHIBITOR | 成都海博为药业有限公司 | 2025-04-17 | — | — | WO | disclosed |
| CN-114989140-B | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | 卡佩拉医疗公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-114940673-B | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | 卡佩拉医疗公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| CN-113302184-B | 1,3, 4-Oxadiazolinone compounds and medicaments | 日本新药株式会社 | 2024-11-22 | — | — | CN | disclosed |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-02-06 | — | — | US | disclosed |
| CN-1100777-C | N-heterocyclic derivatives as NOS inhibitor | BERLEX LAB (US) | 2003-02-05 | — | — | CN | disclosed |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-12-05 | — | — | US | disclosed |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-11-07 | — | — | US | disclosed |
| US-6432947-B1 | NERVOUS SYSTEM DISORDERS; MUSCLE RELAXANTS; ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2002-08-13 | — | — | US | disclosed |
| CN-1252799-A | N-heterocyclic derivatives as NOS inhibitor | BERLEX LAB (US) | 2000-05-10 | — | — | CN | disclosed |
| CN-1199396-A | Novel azepanes and their ring homologues for therapy and prophylaxis of protein kinase mediated diseases | HOFFMANN LA ROCHE (CH) | 1998-11-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069250-A1 | Synthesis by chiral diamine-mediated asymmetric alkylation | SRM, SMOX, DDC | HPGD 2209/4885SMN1; SMN2 3550/4885USP2 1919/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | HPGD 2141/4885SMN1; SMN2 2939/4885USP2 2268/4885 |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | HPGD 12/4885SMN1; SMN2 2568/4885USP2 1630/4885 |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | HPGD 12/4885SMN1; SMN2 2568/4885USP2 1630/4885 |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | HPGD 12/4885SMN1; SMN2 2568/4885USP2 1630/4885 |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | HPGD 12/4885SMN1; SMN2 2568/4885USP2 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.